Drug Profile

ARM 201 - ARCE Therapeutics

Alternative Names: ARM-201 - ARCE Therapeutics

Latest Information Update: 06 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARCE Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Research Gastric cancer; Pancreatic cancer; Prostate cancer; Triple negative breast cancer

19 Dec 2024 Early research in Gastric cancer in Taiwan (Parenteral) (ARCE Therapeutics pipeline, December 2024)
19 Dec 2024 Early research in Pancreatic cancer in Taiwan (Parenteral) (ARCE Therapeutics pipeline, December 2024)
19 Dec 2024 Early research in Prostate cancer in Taiwan (Parenteral) (ARCE Therapeutics pipeline, December 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com